Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 331 Treble Cove Rd NORTH BILLERICA MA 01862 |
Tel: | 1-978-6718842 |
Website: | https://www.lantheus.com |
IR: | See website |
Key People | ||
Mary Anne Heino Chairman of the Board | Paul M. Blanchfield President | Brian A. Markison Chief Executive Officer, Director |
Robert J. Marshall Chief Financial Officer, Treasurer | Daniel M. Niedzwiecki Chief Administrative Officer, General Counsel, Corporate Secretary | Jeffrey Humphrey Chief Medical Officer |
Etienne Montagut Chief Business Officer | Amanda Morgan Chief Commercial Officer | Jean-Claude Provost Chief Medical Officer |
Business Overview |
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others. |
Financial Overview |
For the three months ended 31 March 2024, Lantheus Holdings Inc revenues increased 23% to $370M. Net income totaled $131.1M vs. loss of $2.8M. Revenues reflect PYLARIFY segment increase of 32% to $258.9M, DEFINITY segment increase of 11% to $76.6M. Net Income reflects Interest Income increase from $3.5M to $8.5M (income), Foreign currency losses increase from $246K (expense) to $217K (income). |
Employees: | 834 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,589M as of Mar 31, 2024 |
Annual revenue (TTM): | $1,366M as of Mar 31, 2024 |
EBITDA (TTM): | $535.24M as of Mar 31, 2024 |
Net annual income (TTM): | $460.53M as of Mar 31, 2024 |
Free cash flow (TTM): | $204.99M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 69,312,588 as of Apr 25, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |